for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …

Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed
countries. It is characterized by progressive fibro-calcific remodelling and thickening of the …

Background Previous trials have shown that among high-risk patients with aortic stenosis,
survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical …

Valvular disease remains a major cause of cardiovascular morbidity and mortality
worldwide. 1 Over the past decade, catheter-based interventions in valvular disease have …

Background Transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve
demonstrates good 30 day clinical outcomes in patients with severe aortic stenosis who are …

Summary Background The Placement of Aortic Transcatheter Valves (PARTNER) trial
showed that mortality at 1 year, 2 years, and 3 years is much the same with transcatheter …

Background We compared transcatheter aortic-valve replacement (TAVR), using a self-
expanding transcatheter aortic-valve bioprosthesis, with surgical aortic-valve replacement in …

Background Based on the early results of the Placement of Aortic Transcatheter Valves
(PARTNER) trial, transcatheter aortic valve replacement (TAVR) is an accepted treatment for …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Background: Very little is known about long-term valve durability after transcatheter aortic
valve replacement (TAVR). Objectives: This study sought to evaluate the incidence of …